Inhibitex to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

Business Wire

posted: 15 DAYS 5 HOURS AGO

Text SizeAAA

Inhibitex, Inc. (Nasdaq: INHX), today announced that Russell H. Plumb, president and chief executive officer, will present an overview of the company and its pipeline of differentiated antiviral compounds at the Lazard Capital Markets 6 ^th Annual Healthcare Conference at the St. Regis Hotel in New York City on Tuesday, November 17, 2009 at 1:40 p.m. Eastern Time.

About Inhibitex

Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to treat serious infectious diseases. The Company’s pipeline includes FV-100, its clinical-stage nucleoside analogue in Phase II development for the treatment of herpes zoster (shingles), as well as INX-189, an HCV nucleotide polymerase inhibitor in preclinical development. Inhibitex has also licensed the use of its proprietary MSCRAMM ^® protein technology to Pfizer for the development of staphylococcal vaccines.

For additional information about the Company, please visit www.inhibitex.com.

Inhibitex ^® and MSCRAMM ^® are registered trademark of Inhibitex, Inc.